Boehringer Ingelheim

Zongertinib was the first oral HER2 inhibitor for lung cancer with HER2 mutations, approved in 2025 and moved to first line in 2026.

Beromun is a recombinant form of the immune protein TNF-alpha, pumped with the chemotherapy melphalan through the isolated blood supply of an arm or leg to shrink soft-tissue sarcomas so that the limb can be saved rather than amputated.

Afatinib (Gilotrif) is a second-generation pill that binds EGFR, HER2 and HER4 irreversibly, approved in 2013 for EGFR-mutant lung cancer. Its lasting value is activity against the uncommon EGFR mutations G719X, L861Q and S768I, approved in 2018, because osimertinib has displaced it for common mutations and its wild-type EGFR binding causes more rash and diarrhoea.

Brigimadlin is a tablet that frees the p53 'guardian' protein from MDM2, the protein that liposarcomas make in excess to keep p53 switched off. It is being compared with doxorubicin as first treatment for dedifferentiated liposarcoma in a phase 2/3 trial.

Nintedanib is a triple angiokinase inhibitor pill (VEGFR, FGFR, PDGFR) approved for pulmonary fibrosis and, in the EU, for second-line lung adenocarcinoma with docetaxel. In mesothelioma the phase 2 part of LUME-Meso suggested slower progression in epithelioid disease, but the phase 3 part showed none, a much-cited warning about small randomised phase 2 signals.

Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung.